Ost-müük MyMD Pharmaceuticals, Inc. - MYMD CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | - | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | N/A |
Avatud* | N/A |
Aastane muutus* | N/A |
Päeva ulatus* | N/A |
52 nädala ulatus | 0.90-6.15 |
Keskmine maht (10 päeva) | 605.53K |
Keskmine maht (3 kuud) | 11.90M |
Turukapitalisatsioon | 68.52M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 39.61M |
Tulu | N/A |
EPS | -0.33 |
Dividendid (% kasumist) | N/A |
Beeta | 2.20 |
Järgmine tuluaruande kuupäev | Aug 14, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|
MyMD Pharmaceuticals, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
Monday, August 14, 2023 | ||
Kellaaeg (UTC) (UTC) 12:30 | Riik US
| Sündmus Q2 2023 MyMD Pharmaceuticals Inc Earnings Release Q2 2023 MyMD Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Wednesday, November 8, 2023 | ||
Kellaaeg (UTC) (UTC) 21:00 | Riik US
| Sündmus Q3 2023 MyMD Pharmaceuticals Inc Earnings Release Q3 2023 MyMD Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 1.66557 |
Tulu | 0 | 0 | 0 | 0 | 1.66557 |
Kulud, Kokku | 0 | 0 | 0 | 0 | 1.53829 |
Brutokasum | 0 | 0 | 0 | 0 | 0.12728 |
Kogu tegevuskulu | 15.2783 | 29.8948 | 12.2857 | 3.4721 | 12.5062 |
Müük/Üldine/admin kulud, kokku | 6.21534 | 21.4561 | 4.32203 | 3.3971 | 7.44833 |
Uuringud ja arendus | 9.06742 | 6.7451 | 7.96368 | 0 | 1.06325 |
Depreciation / Amortization | 0 | 0.17111 | |||
Ootamatud kulutused (tulu) | -0.00444 | 1.08505 | 0 | 0.075 | 2.28524 |
Tulud majandustegevusest | -15.2783 | -29.8948 | -12.2857 | -3.4721 | -10.8406 |
Intressitulud (kulu), muud tulud, neto | 0.08099 | 0.00571 | 0.13653 | 0.10038 | 0.14394 |
Netotulu enne makse | -15.1973 | -29.889 | -12.1522 | -3.3813 | -10.849 |
Netotulu pärast makse | -15.1973 | -29.889 | -12.1522 | -3.3813 | -10.849 |
Netotulu enne erikulusid | -15.1973 | -29.889 | -12.1522 | -3.3813 | -10.849 |
Netotulu | -15.1973 | -29.889 | -17.5806 | -3.88825 | -10.849 |
Arvestatav tulu, v a erikulud | -15.1973 | -29.889 | -12.1522 | -3.3813 | -10.849 |
Arvestatav tulu, koos erikuludega | -15.1973 | -29.889 | -17.5806 | -3.88825 | -10.849 |
Jaotamisele kuuluv netotulu | -15.1973 | -29.889 | -17.5806 | -3.88825 | -10.849 |
Keskmine jaotamisele kuuluv aktsia kohta | 38.8258 | 35.0172 | 3.52634 | 0.30634 | 0.22864 |
Jaotatav EPS, v a erakorralised kulud | -0.39142 | -0.85355 | -3.44612 | -11.0379 | -47.4503 |
Jaotamisele kuuluv normaal-EPS | -0.39154 | -0.82257 | -3.44526 | -10.7618 | -36.771 |
Muud, neto | 0.00417 | ||||
Gain (Loss) on Sale of Assets | -0.00304 | -0.00958 | -0.15649 | ||
Erakorralised kulud kokku | -5.4284 | -0.50695 | |||
Other Operating Expenses, Total | 0 | 0.60846 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Tulu | 0 | 0 | 0 | 0 | 0 |
Kulud, Kokku | 0 | 0 | 0 | 0 | 0 |
Brutokasum | 0 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 2.59032 | 3.80804 | 3.70989 | 3.64298 | 4.11741 |
Müük/Üldine/admin kulud, kokku | 1.05706 | 1.33756 | 1.90666 | 1.47901 | 1.49211 |
Uuringud ja arendus | 0.77043 | 2.47048 | 1.80323 | 2.16397 | 2.62974 |
Intressikulu (tulu) - neto majandustegevusest | 0 | 0 | 0 | ||
Ootamatud kulutused (tulu) | 0 | 0 | 0 | 0 | -0.00444 |
Tulud majandustegevusest | -2.59032 | -3.80804 | -3.70989 | -3.64298 | -4.11741 |
Intressitulud (kulu), muud tulud, neto | 1.19929 | 0.06252 | 0.01615 | 0.00693 | -0.00462 |
Netotulu enne makse | -1.51173 | -3.74552 | -3.69374 | -3.63604 | -4.12203 |
Netotulu pärast makse | -1.51173 | -3.74552 | -3.69374 | -3.63604 | -4.12203 |
Netotulu enne erikulusid | -1.51173 | -3.74552 | -3.69374 | -3.63604 | -4.12203 |
Netotulu | -1.51173 | -3.74552 | -3.69374 | -3.63604 | -4.12203 |
Arvestatav tulu, v a erikulud | -1.67007 | -3.74552 | -3.69374 | -3.63604 | -4.12203 |
Arvestatav tulu, koos erikuludega | -1.67007 | -3.74552 | -3.69374 | -3.63604 | -4.12203 |
Jaotamisele kuuluv netotulu | -1.67007 | -3.74552 | -3.69374 | -3.63604 | -4.12203 |
Keskmine jaotamisele kuuluv aktsia kohta | 39.7872 | 39.7966 | 39.0468 | 38.3264 | 38.1229 |
Jaotatav EPS, v a erakorralised kulud | -0.04197 | -0.09412 | -0.0946 | -0.09487 | -0.10812 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.04197 | -0.09412 | -0.0946 | -0.09487 | -0.10824 |
Other Operating Expenses, Total | 0.76283 | 0 | |||
Depreciation / Amortization | 0 | ||||
Muud, neto | -0.1207 | 0 | |||
Total Adjustments to Net Income | -0.15833 | 0 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Käibevarad kokku | 5.40178 | 12.6654 | 36.8428 | 10.3108 | 6.67013 |
Raha ja lühiajalised investeeringud | 4.83599 | 11.559 | 35.3364 | 9.68172 | 5.45475 |
Raha ja ekvivalendid | 0.74909 | 0.55597 | 0.18176 | ||
Lühiajalised investeeringud | 4.0869 | 11.0031 | 16.7185 | 9.16427 | 5.273 |
Laekumata arved, neto | 1.20001 | 0.04288 | 0.18567 | ||
Accounts Receivable - Trade, Net | 0.04288 | 0.17633 | |||
Total Inventory | 0.19899 | 0.58527 | |||
Prepaid Expenses | 0.56579 | 1.10635 | 0.29434 | 0.38723 | 0.44444 |
Total Assets | 17.54 | 24.8129 | 36.8428 | 10.8849 | 7.80725 |
Property/Plant/Equipment, Total - Net | 0.13966 | 0.14901 | 0.03357 | 0.08346 | |
Property/Plant/Equipment, Total - Gross | 2.13687 | ||||
Accumulated Depreciation, Total | -2.1033 | ||||
Intangibles, Net | 0.17042 | 0.24341 | |||
Other Long Term Assets, Total | 0 | 0.37012 | 0.81026 | ||
Total Current Liabilities | 2.76898 | 1.03987 | 2.2633 | 1.52977 | 1.9735 |
Accounts Payable | 2.35656 | 0.86752 | 2.2039 | 0.65729 | 1.9735 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.02998 | 0 | 0.05939 | ||
Total Liabilities | 2.84492 | 1.16576 | 2.2633 | 1.52977 | 1.9735 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 14.6951 | 23.6472 | 34.5795 | 9.35517 | 5.83375 |
Redeemable Preferred Stock | 0.14452 | 0.14452 | 0.14452 | 0 | 0 |
Common Stock | 108.309 | 102.064 | 171.599 | 128.92 | 121.555 |
Retained Earnings (Accumulated Deficit) | -93.7589 | -78.5616 | -137.164 | -119.583 | -115.695 |
Other Equity, Total | 0 | 0.01789 | -0.02591 | ||
Total Liabilities & Shareholders’ Equity | 17.54 | 24.8129 | 36.8428 | 10.8849 | 7.80725 |
Total Common Shares Outstanding | 39.47 | 37.6731 | 8.79263 | 0.86942 | 0.26006 |
Total Preferred Shares Outstanding | 0.07299 | 0.07299 | 0.07299 | 0 | 0 |
Cash | 18.618 | 0.51744 | |||
Accrued Expenses | 0.38245 | 0.17235 | 0.87247 | ||
Other Current Assets, Total | 0.012 | ||||
Goodwill, Net | 10.4985 | 10.4985 | |||
Long Term Investments | 1.5 | 1.5 | |||
Current Port. of LT Debt/Capital Leases | 0 | ||||
Long Term Debt | 0 | 0 | |||
Other Liabilities, Total | 0.07594 | 0.12589 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 16.2866 | 5.40178 | 8.07744 | 6.99241 | 10.0722 |
Raha ja lühiajalised investeeringud | 15.5485 | 4.83599 | 7.08431 | 5.621 | 9.18811 |
Cash | |||||
Lühiajalised investeeringud | 15.36 | 4.0869 | 6.77438 | 4.50583 | 7.99889 |
Laekumata arved, neto | |||||
Prepaid Expenses | 0.73814 | 0.56579 | 0.99313 | 1.37141 | 0.88412 |
Other Current Assets, Total | |||||
Total Assets | 28.409 | 17.54 | 20.2311 | 19.1612 | 22.2035 |
Other Long Term Assets, Total | |||||
Total Current Liabilities | 1.62552 | 2.76898 | 1.78093 | 2.90305 | 2.46678 |
Accounts Payable | 1.19926 | 2.35656 | 1.39268 | 2.61811 | 1.9961 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.18832 | 0.02998 | |||
Total Liabilities | 14.4021 | 2.84492 | 1.90406 | 3.04283 | 2.58138 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 14.007 | 14.6951 | 18.327 | 16.1183 | 19.6221 |
Redeemable Preferred Stock | 1.05741 | 0.14452 | 0.14452 | 0.14452 | 0.14452 |
Common Stock | 108.379 | 108.309 | 108.196 | 102.293 | 102.161 |
Retained Earnings (Accumulated Deficit) | -95.429 | -93.7589 | -90.0134 | -86.3196 | -82.6836 |
Total Liabilities & Shareholders’ Equity | 28.409 | 17.54 | 20.2311 | 19.1612 | 22.2035 |
Total Common Shares Outstanding | 39.47 | 39.47 | 39.47 | 38.0583 | 38.0583 |
Total Preferred Shares Outstanding | 0.08799 | 0.07299 | 0.21135 | 0.07299 | 0.07299 |
Raha ja ekvivalendid | 0.18855 | 0.74909 | 0.30993 | 1.11517 | 1.18922 |
Property/Plant/Equipment, Total - Net | 0.12382 | 0.13966 | 0.15513 | 0.17023 | 0.13275 |
Goodwill, Net | 10.4985 | 10.4985 | 10.4985 | 10.4985 | 10.4985 |
Long Term Investments | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
Accrued Expenses | 0.23795 | 0.38245 | 0.38826 | 0.28495 | 0.47069 |
Other Liabilities, Total | 12.7765 | 0.07594 | 0.12313 | 0.13977 | 0.1146 |
Current Port. of LT Debt/Capital Leases | |||||
Long Term Debt | 0 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -15.1973 | -29.889 | -12.1522 | -3.88825 | -10.849 |
Raha majandustegevusest | -12.2701 | -19.5165 | -11.9249 | -3.07428 | -8.50219 |
Raha majandustegevusest | 0.02945 | 0.07406 | 0.23449 | ||
Mittelikviidsed varad | 0.6982 | 15.5544 | -0.62432 | 0.91945 | 1.42741 |
Muutused tööjõus | 2.22907 | -5.18186 | 0.82214 | -0.17955 | 0.68495 |
Tulu investeeringutelt | 6.91316 | 19.8506 | -8.75747 | -3.94063 | -0.35969 |
Kapitalikulutused | 0 | -0.06821 | |||
Muud rahavood investeeringutelt, kokku | 6.91316 | 19.8506 | -8.75747 | -3.94063 | -0.29147 |
Rahaline kogumuutus | 0.19312 | 0.40768 | 17.9854 | -0.04922 | 0.24332 |
Rahavood investeeringutelt | 5.55003 | 0.07353 | 38.6678 | 6.96569 | 9.1052 |
Aktsiate emiteerimine (tagasiost), neto | 5.55003 | 1.18984 | 38.6678 | 6.96569 | 9.1052 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0.00207 |
Makstud intressid | 0 | 0.2718 | 0 | 0 | 0 |
Amortization | 0 | ||||
Laenu väljastamine (kustutamine), neto | 0 | -1.11631 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -1.51173 | -15.1973 | -11.4518 | -7.75808 | -4.12203 |
Cash From Operating Activities | -3.97164 | -12.2701 | -10.0217 | -5.93425 | -2.36618 |
Non-Cash Items | -0.9837 | 0.6982 | 0.58476 | 0.23304 | 0.10174 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Cash Interest Paid | 0 | 0 | 0 | 0 | 0 |
Changes in Working Capital | -1.47622 | 2.22907 | 0.8454 | 1.59079 | 1.65411 |
Cash From Investing Activities | -11.2746 | 6.91316 | 4.2256 | 6.49345 | 2.99944 |
Other Investing Cash Flow Items, Total | -11.2746 | 6.91316 | 4.2256 | 6.49345 | 2.99944 |
Cash From Financing Activities | 14.6857 | 5.55003 | 5.55003 | 0 | 0 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
Net Change in Cash | -0.56054 | 0.19312 | -0.24604 | 0.55921 | 0.63326 |
Amortization | 0 | ||||
Issuance (Retirement) of Stock, Net | 14.6857 | 5.55003 | 5.55003 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Williams (Caroline C) | Individual Investor | 9.4545 | 3744451 | 2471479 | 2023-03-09 | LOW |
Duffey (Samuel S) | Individual Investor | 5.1732 | 2048862 | 2048862 | 2022-06-07 | |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.6821 | 1458295 | 0 | 2023-03-31 | LOW |
Mirae Asset Global Investments (USA) LLC | Investment Advisor | 2.9633 | 1173610 | 417125 | 2023-03-31 | LOW |
Abbe (Richard) | Individual Investor | 2.1848 | 865294 | -1052948 | 2022-12-31 | |
Horizons ETFs Management (Canada) Inc. | Investment Advisor/Hedge Fund | 0.7477 | 296145 | -1532 | 2023-04-30 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6976 | 276298 | 0 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.5012 | 198513 | 7336 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3036 | 120252 | 18500 | 2023-03-31 | LOW |
Premas Biotech Pvt. Ltd. | Corporation | 0.262 | 103782 | 0 | 2023-03-09 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.2489 | 98592 | 27026 | 2023-03-31 | MED |
Silverman (Joshua) | Individual Investor | 0.2242 | 88776 | 0 | 2023-03-09 | LOW |
Schreiber (Christopher C) | Individual Investor | 0.2228 | 88238 | 0 | 2023-03-09 | LOW |
Wells Fargo Advisors | Research Firm | 0.1894 | 75000 | 75000 | 2023-03-31 | LOW |
White (Billy Joe) | Individual Investor | 0.1863 | 73776 | 0 | 2023-03-09 | LOW |
M Holdings Securities, Inc. | Investment Advisor | 0.179 | 70909 | 0 | 2023-03-31 | LOW |
Cambria Investment Management, L.P. | Investment Advisor/Hedge Fund | 0.1564 | 61956 | -6884 | 2023-03-31 | MED |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1517 | 60090 | 4734 | 2023-03-31 | LOW |
Fidelis Capital | Investment Advisor | 0.0974 | 38590 | 0 | 2023-03-31 | HIGH |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.0956 | 37874 | -143084 | 2023-03-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group535K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$113M+
Igakuine investeerimise maht
$64M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
MyMD Pharmaceuticals, Inc. Company profile
Ettevõttest MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc., varem Akers Biosciences, Inc., on kliinilises staadiumis farmaatsiaettevõte. Ettevõte keskendub kahe terapeutilisel sihtmärgil põhineva raviplatvormi - MYMD-1 ja Supera-CBD - arendamisele ja turustamisele. MyMD-1 on kliinilises staadiumis väike molekul, mis reguleerib immuunsüsteemi, et ravida autoimmuunhaigusi, sealhulgas hulgiskleroosi, diabeeti, reumatoidartriiti ja põletikulisi soolehaigusi. MyMD-1 on väljatöötamisel vanusega seotud haiguste, näiteks nõrkuse ja sarkopeenia raviks. MyMD-1 toimib paljude põletikuvastaste tsütokiinide, nagu TNF-α, interleukiin 6 (IL-6) ja interleukiin 17 (IL-17), vabanemise reguleerimise kaudu. Supera-CBD on Cannabidioli (CBD) sünteetiline derivaat, mida töötatakse välja erinevate seisundite, sealhulgas, kuid mitte ainult, epilepsia, valu ja ärevuse või depressiooni raviks.
Industry: | Biotechnology & Medical Research (NEC) |
855 N. Wolfe Street
Suite 623
21205
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 535,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com